Open in interactive viewer → charts, metric popovers & call review

Avon Technologies Wants a Smaller Order Book and a Much Bigger Company

Star is finished, margins are at record levels, and the helmet maker is now telling defense analysts that backlog is a liability — while auditioning as a serial acquirer.
AVON.L · Earnings Call · 2026-11-10

The last year of Star, and the first of something else

Avon Technologies closed FY2026 with the sort of hyphenated scorecard a turnaround CEO dreams about: revenue up 13%, adjusted operating profit up 51% to $60.7 million, operating margin at 17.2% (a 440 basis point step-up), EPS of $1.43 up 57%, return on invested capital of 27.6% and cash conversion of 93%. Net debt fell more than 30% and leverage sits near 0.4x. Every medium-term target set in 2023 was beaten. The Strengthen System — Avon's home-grown continuous improvement machinery, with 200-odd certified practitioners — is now the product of the story rather than the project. But the interesting content is in what comes next. Three years ago this was a company relearning how to run a factory. Today it is auditioning as a capital allocator. The new framing is "improve, grow and compound," and the compounding half leans on a large investable universe: a $15–20 billion protection-technology addressable market, a five-year ambition of more than $600 million of revenue with returns above 18%, and a stated willingness to buy businesses and apply the improvement playbook to them. That is a sharp change in tone from May, when the same management team was asked about M&A and essentially ducked:

At the moment, we've still got quite a lot to do with our existing businesses... so far, we're actually not spending a lot of time thinking about it. So I'm going to duck your question for now.

Mark Sclater, CEO or Senior Executive · 2026-05-13
Six months later, the CEO is pointing out that he was head of corporate finance at a FTSE 100 and the CFO held the same role at a FTSE 250 — "between us, I think we've got the M&A side pretty well under control" — and sketching a buy-improve-grow-reinvest cycle. Strategically, that is the signal of the report.

The backlog heresy

Order intake nudged up to $354 million and the closing order book held at last year's record $263 million, which is where the conventional defense narrative usually ends. Avon's CEO went the other way entirely:

The way we look at it is the less order book, the better... we look at it more as more akin to a fast-moving consumer goods company. If you order a helmet, you don't want it in 6 months. You want it next week.

Mark Sclater, Chief Executive Officer · 2026-11-10
Asked directly whether book-to-bill below 1 is the goal, the answer was yes — revenue up, backlog down. The reasoning is that lead times are the real competitive weapon: roughly four weeks on commercial helmets versus quotes of many months from rivals, with the capacity to surge to a couple of weeks if a police department is desperate. Flow manufacturing took Cleveland from 20,000 helmets a year to 200,000 without adding a single press, and hybrid tooling is expected to push it past 300,000 this year. That is a genuinely company-unique argument, and it cuts against how the sell-side reads this sector. It also reframes the guidance. Management expects orders to dip before they recover as ACH hits its contract ceiling and IHPS migrates to a high-cut version — and insists there is enough cover to bridge the gap. The prize here is the rifle helmet: very few manufacturers globally can make rifle-rated protection, and the U.S. Department of War's shift toward survivability-plus-mobility plays directly into Avon's differentiated line. "The opportunity in IHPS is much better than we were expecting it to be," the CEO said, adding he is "quietly confident" over the next two to three years. A fresh $4.5 million DoW-funded R&D contract on the Team Wendy side, disclosed mid-Q&A, underwrites the next generation.

Reliability exits, inventory turns enter

The vocabulary rotation is telling. In May, the dominant operational word was reliability — machine downtime, Friday absenteeism, a supply chain running hand-to-mouth after production doubled: “So production reliability has been an issue in the last 3 months... we are outstripping our supply chain's ability to deliver to us.” — Mark Sclater, CEO or Senior Executive · 2026-05-13 That word has essentially vanished from the current call, replaced by inventory turns at the top of the company's own keyword stack. Management is refreshingly blunt that this is the miss: turns improved only 14% against a loftier target, and the CEO admits being "a little disappointed to have fallen short." Annual bonuses are now explicitly tied to roughly a turn a year. The CFO laid out the mechanics: finished goods stacked up awaiting government inspection, and raw material was deliberately pre-bought to protect the production ramp — both unwind through FY2027. The CEO's framing of the trade-off is the useful bit — turns are always read alongside on-time delivery, with a target in the high nineties percent, and the real enemy is right-first-time quality that forces rework.

Cash, politics, and the price of compounding

The cash bridge is the reason the acquisition talk is credible. With transformation costs gone, pension contributions falling and working capital releasing, Avon guides FY2027 free cash flow of $50–60 million versus $31 million. Group revenue growth is guided to mid-single digits, with operating margin held in the 16–18% range, absorbing both further dilution from low-margin ACH volume and the normalization of Avon Protection's unusually rich 22.5% margin — which benefited from non-recurring high-margin product sales and $13 million of Ukraine-related demand that now laps. The core respiratory franchise remains the quiet annuity: close to half a million masks into NATO countries, roughly two million in the U.S., each placement seeding filters, spares and sustainment; a sole-source DoW filter award after a competitor exited; and a new common voice projection unit with 5,000 units ordered and a pipeline claimed above $100 million, now NIOSH-certified. The political risk is unusually candid. Post-midterms, the CEO flagged that grant funding skews toward Republican states and that "a few more Democratic states is not particularly helpful," while a second government shutdown would delay the grant wave underpinning U.S. commercial helmet demand. Investors should weigh that against a stock with no price tape supplied in this dataset — the market's verdict on all of this is simply not observable here, which is a real gap in the evidence. What is observable: a ~$920 million market cap company that has finished fixing itself, is generating cash faster than it can plausibly reinvest organically, and has just told you it intends to go shopping. The interesting question for 2027 is no longer whether Avon can run a factory. It is whether it can be trusted with a balance sheet.